骨髓增生异常综合征核心结局指标集的开发——EUMDS注册组的一项德尔菲研究
该研究旨在建立首个骨髓增生异常综合征核心结局指标集(MDS-COS),通过系统文献综述提取患者和/或临床相关结局,由欧洲白血病网MDS(EUMDS)临床专家确定26个潜在核心结局并进行三轮德尔菲调查。第一轮56名专家后15个结局符合纳入标准并额外纳入1个,第二轮38名专家后纳入6个结局,第三轮对6个纳入结局及其定义进行合理性和可行性最终检查。最终MDS-COS包括健康相关生活质量、治疗相关死亡率、总生存期、体能状态、安全性和血液学改善。
要点
- 最终MDS-COS包括健康相关生活质量、治疗相关死亡率、总生存期、体能状态、安全性和血液学改善。
- 第一轮56名专家后15个结局符合纳入标准并额外纳入1个。
- 第二轮38名专家后纳入6个结局,第三轮对6个结局及定义进行合理性和可行性检查。
核心结论
- 新开发的MDS-COS是首个最低结局集合,旨在增强未来MDS研究之间的可比性并促进对治疗效果的更好理解。
研究设计与样本
- 研究对MDS研究进行 comprehensive 系统文献综述以提取患者和/或临床相关结局。
- 来自欧洲白血病网MDS(EUMDS)的临床专家确定26个潜在MDS核心结局并参与三轮德尔菲调查。
- 第一轮调查有56名专家参与,第二轮有38名专家参与,第三轮对6个纳入结局及其定义进行合理性和可行性最终检查。
主要发现
- 第一轮调查(56名专家)后,15个结局符合纳入标准,并额外纳入1个结局。
- 第二轮调查(38名专家)后纳入6个结局。
- 最终MDS-COS包括健康相关生活质量、治疗相关死亡率、总生存期、体能状态、安全性和血液学改善。
关键数值与推荐
- 最终MDS-COS包含6个结局:健康相关生活质量、治疗相关死亡率、总生存期、体能状态、安全性和血液学改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment options for myelodysplastic syndromes (MDS) vary widely, depending on the natural disease course and patient-related factors. Comparison of treatment effectiveness is challenging as different endpoints have been included in clinical trials and outcome reporting. Our goal was to develop the first MDS core outcome set (MDS-COS) defining a minimum set of outcomes that should be reported in future clinical studies. We performed a comprehensive systematic literature review among MDS studies to extract patient- and/or clinically relevant outcomes. Clinical experts from the European LeukemiaNet MDS (EUMDS) identified 26 potential MDS core outcomes and participated in a three-round Delphi survey. After the first survey (56 experts), 15 outcomes met the inclusion criteria and one additional outcome was included. The second round (38 experts) resulted in six included outcomes. In the third round, a final check on plausibility and practicality of the six included outcomes and their definitions was performed. The final MDS-COS includes: health-related quality of life, treatment-related mortality, overall survival, performance status, safety, and haematological improvement. This newly developed MDS-COS represents the first minimum set of outcomes aiming to enhance comparability across future MDS studies and facilitate a better understanding of treatment effectiveness.
引用
- Rochau U, Stojkov I, Conrads-Frank A, et al. Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group. Br J Haematol. 2020. PMID: 32410281. doi:10.1111/bjh.16654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。